

1103326-0525 Div 2IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Berg, et al.
Serial No. : 10/714,577
Filed : November 13, 2003
Examiner : R. Desai
Group Art Unit : 1625
For : SUBSTITUTED CHROMAN DERIVATIVES

RECEIVED
CENTRAL FAX CENTER
MAR 22 2006

TERMINAL DISCLAIMER

The owner, AstraZeneca AB, of 100% interest in the instant application hereby through its undersigned agent, who is empowered to act on behalf of AstraZeneca AB, disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. §§154-156 and 173, as presently shortened by any terminal disclaimer, of prior Patent No. 6,387,899. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application which would extend to the expiration date of the full

statutory term as defined in 35 U.S.C. §§154-156 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. §1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that the statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Dated: March 22, 2006

Respectfully submitted



Richard J. Sterner

Reg. No. 35,372

Customer Number 007470
(212) 819-8200

Agent's Direct Line:
(212) 819-8783